Validity of the Patient Health Questionnaire-9 in neurologic populations

Conclusions Despite theoretical concerns about its validity, the PHQ-9 performed well at its standard cut-point of 10. Consistent with the literature, being able to use a validated, brief tool that is available publicly should improve case finding of depression in neurologic populations. When considering clinical practicality along with the findings of this analyzed, this study confirmed that the PHQ-9 is valid in a general outpatient neurologic population.
Source: Neurology Clinical Practice - Category: Neurology Authors: Tags: Cost effectiveness/economic, Diagnostic test assessment, All Clinical Neurology, Depression, All epidemiology Research Source Type: research

Related Links:

OBJECTIVES: To describe short- and long-term neurologic prognosis of patients with thrombotic thrombocytopenic purpura and to identify clusters associated with evolution. DESIGN: Prospective French cohort. SETTING: ICU in a reference center. PATIENTS: All consecutive patients with newly diagnosed thrombocytopenic purpura. INTERVENTION: Comprehensive clinical, biological, and radiological evaluation at admission. Neurocognitive recovery was assessed using Glasgow Outcome Scale (range 1–5, with 1 representing death and 5 representing no or minimal neurologic deficit). MEASUREMENTS AND...
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Clinical Investigations Source Type: research
CONCLUSIONS: Gaps in memory and various memory types were common after ICU admission, whose prevalence waned over time. Compared with nightmares and fearful memories, gaps in memories were most strongly associated with poor mental health and quality of life. Identifying patients with gaps in memories might be an objective way of planning interventions to improve their long-term outcomes.
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Clinical Investigations Source Type: research
Hello, I’m a PGY3 Neurology resident applying fir fellowship this year. I am thinking between Neuro-Ophthalmology (because is chill and lux and have good life style) epilepsy (because I think it might be good job opportunities) and vascular (field that I’ve done alot of research projects in and initially was my favorite but I’m not a fan if life style and being oncall anymore) I recently heard that neuromuscular has the best job market among all of sub-specialities in neurology. I would... Read more
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Neurology Source Type: forums
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusion: The Turkish version of Neuro-QoL-Stigma has satisfactory content validity and high internal consistency. Neuro-QoLStigma is suitable for understanding stigmatization in different neurological disorders in the Turkish population. The scale is available for use at http://www.healthmeasures.net/explore-measurement-systems/neuro-qol. PMID: 31023004 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Publication date: 2018Source: International Review of Neurobiology, Volume 139Author(s): Panagiotis Zis, Dimos-Dimitrios MitsikostasAbstractPlacebo is an intervention with no therapeutic effect that is used as a control in randomized controlled trials (RCTs). Placebo effects and responses can produce a beneficial effect that cannot be attributed to the properties of the intervention itself, since it is usually inactive, and should, therefore, be due to the patient's expectations about treatment (placebo effects), or confounding factors such as natural history, co-interventions, biases, among other co-factors (placebo respo...
Source: International Review of Neurobiology - Category: Neuroscience Source Type: research
Publication date: Available online 2 August 2018Source: International Review of NeurobiologyAuthor(s): Panagiotis Zis, Dimos-Dimitrios MitsikostasAbstractPlacebo is an intervention with no therapeutic effect that is used as a control in randomized controlled trials (RCTs). Placebo effects and responses can produce a beneficial effect that cannot be attributed to the properties of the intervention itself, since it is usually inactive, and should, therefore, be due to the patient's expectations about treatment (placebo effects), or confounding factors such as natural history, co-interventions, biases, among other co-factors ...
Source: International Review of Neurobiology - Category: Neuroscience Source Type: research
iev G Abstract The neuroimmune system represents a dense network of biochemical signals associated with neurotransmitters, neuropeptides, neurohormones, cytokines, chemokines, and growth factors synthesized in neurons, glial cells and immune cells, to maintain systemic homeostasis. Endogenous and/or exogenous, noxious stimuli in any tissue are captured by sensor cells to inform the brain; likewise, signals originating at the central nervous system (CNS) level are transmitted to peripheral immune effectors which react to central stimuli. This multidirectional information system makes it possible for the CNS to resp...
Source: Epilepsy Curr - Category: Neurology Authors: Tags: Curr Pharm Des Source Type: research
The objectives of treatments of neurodegenerative disorders include primary prevention, slowing or arrest of disease progression, and control of symptoms. Stroke is an acute clinical condition causing frequent disability and death, with only one approved treatment. There are many challenges to acute stroke clinical trials; among them, the very short therapeutic window and the issue of stroke heterogeneity. In this chapter, only the core elements of the study designs are outlined. KEY MESSAGES: The design of an RCT must be adapted to the basic characteristics of each clinical condition. PMID: 27463686 [PubMed - in process]
Source: Frontiers of Neurology and Neuroscience - Category: Neuroscience Tags: Front Neurol Neurosci Source Type: research
CONCLUSION: Physical activity could represent an additional approach to fight against such diseases. PMID: 27121507 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
More News: Brain | Depression | Epidemiology | Epilepsy | Headache | Migraine | Multiple Sclerosis | Neurology | Parkinson's Disease | Psychiatry | Statistics | Stroke | Study